other material
confidence high
sentiment neutral
materiality 0.60
Karyopharm issues $20M Series A convertible preferred stock to settle forbearance fees
Karyopharm Therapeutics Inc.
- Issued 20,000 shares of 0% Series A Convertible Perpetual Preferred, $1,000 liquidation preference each, on Sept 17, 2026.
- Convertible into common at $1.62/share; capped at 4,520,000 shares until stockholder consent, with cash settlement for excess.
- Preferred ranks senior to common; holders can force repurchase at $1,000 after Sept 17, 2029 or on fundamental changes.
- Company must seek stockholder approval by March 15, 2027; deferred cash settlement until then if conversion exceeds cap.